Table 1 Baseline characteristics of study population
Variables | All subjects (n = 2631) | Quartile 1 (n = 658) | Quartile 2 (n = 653) | Quartile 3 (n = 661) | Quartile 4 (n = 659) | P value for trend |
|---|---|---|---|---|---|---|
hs-cTnT range (ng/L) |  | < 8.2 | 8.2–13 | 13–21.6 | ≥ 21.6 |  |
Age (years) | 65 ± 11.2 | 59.9 ± 10 | 63.4 ± 10.5 | 68.3 ± 10 | 68.4 ± 11.9 | < 0.001 |
Male (%) | 72.4 | 66.3 | 75.2 | 75.2 | 73.1 | 0.001 |
BMI (kg/m2) | 28.4 (25.4–31.9) | 28.6 (25.8–32.7) | 28.7 (25.8–32) | 28.1 (25.4–31.3) | 27.7 (24.9–31.6) | 0.001 |
HbA1c (%) | 5.8 (5.5–6.0) | 5.7 (5.5–6.0) | 5.8 (5.5–6.0) | 5.8(5.4–6.0) | 5.8(5.5–6.0) | 0.094 |
(mmol/mol) | 39.9 (36.6–42.1) | 38.8 (36.6–42.1) | 39.9 (36.6–42.1) | 39.9 (35.5–42.1) | 39.9 (36.6–42.1) |  |
Fasting blood glucose (mg/dL) | 103.2 (95.2–110) | 103 (94.9–110) | 102.9 (94.7–110) | 103.6 (97.2–110) | 103.8 (95.1–110) | 0.438 |
Risk factors | ||||||
 Hypertension (%) | 71 | 64 | 68 | 76 | 77 | < 0.001 |
 Former/current smokers (%) | 67 | 65 | 70 | 67 | 66.5 | 0.394 |
 CVD (%) | 78.8 | 67.6 | 72.9 | 84.3 | 90.4 | < 0.001 |
 CAD (%) | 74.8 | 63.1 | 70 | 78.3 | 87.8 | < 0.001 |
 PAD (%) | 24.7 | 17.2 | 19.3 | 32.1 | 30 | < 0.001 |
Laboratory data | ||||||
 LDLc (mg/dL) | 97 (79–119) | 100 (82–122) | 98 (81–120) | 95.5 (77–116) | 96 (79–117) | 0.032 |
 HDLc (mg/dL) | 37 (31–46) | 37 (31–46) | 37 (31–45) | 38 (31–47) | 36 (30–45) | 0.106 |
 TG (mg/dL) | 118 (85–169) | 124 (86–179) | 117 (87–172) | 111 (83–157) | 121 (88–173) | 0.004 |
 hsCRP (mg/L) | 2.3 (1.0–5.3) | 1.8 (0.8–3.9) | 1.9 (0.9–3.6) | 2.0 (0.9–4.4) | 5.3 (1.9–13.5) | < 0.001 |
 eGFR (mL/min per 1.73 m2) | 83.7 (68.6–94.3) | 90.3 (79.7–98.4) | 85.2 (73.7–95.6) | 78.9 (65.0–91.0) | 76.2 (58.5–91.0) | < 0.001 |
Medications | ||||||
 ACEi/ARB (%) | 46.6 | 37.5 | 46.4 | 50.5 | 52 | < 0.001 |
 β-Blockers (%) | 60.6 | 58.7 | 61.7 | 62.5 | 59.6 | 0.456 |
 Statins (%) | 57.7 | 55.9 | 60 | 58.5 | 56.3 | 0.388 |
 Aspirin (%) | 73 | 74.8 | 74.1 | 72.3 | 70.9 | 0.37 |